222 related articles for article (PubMed ID: 23512078)
21. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients.
Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP
Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759
[TBL] [Abstract][Full Text] [Related]
22. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
[TBL] [Abstract][Full Text] [Related]
23. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
24. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
25. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
27. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
Rutkowski P; Nowecki ZI; Kulik J; Ruka W; Siedlecki JA
Melanoma Res; 2008 Aug; 18(4):246-52. PubMed ID: 18626308
[TBL] [Abstract][Full Text] [Related]
28. A single-institution validation of the AJCC staging system for stage IV melanoma.
Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG
Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172
[TBL] [Abstract][Full Text] [Related]
29. [The prognostic role of clinical factors, VEGF, IL-8 and sTNF-R1 in cutaneous melanomas at locoregional stage].
Ługowska I; Kowalska M; Zdzienicki M; Fuksiewicz M; Kamińska J; Szamotulska K; Rutkowski P
Pol Merkur Lekarski; 2012 Jan; 32(187):22-7. PubMed ID: 22400175
[TBL] [Abstract][Full Text] [Related]
30. Sarcopenia as a prognostic factor among patients with stage III melanoma.
Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
[TBL] [Abstract][Full Text] [Related]
31. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
[TBL] [Abstract][Full Text] [Related]
33. Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma.
Bagaria SP; Ray PS; Joseph RW; Heckman MG; Rawal B; Gray RJ; Pockaj B; Wasif N
Cancer; 2013 May; 119(10):1860-7. PubMed ID: 23408288
[TBL] [Abstract][Full Text] [Related]
34. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
35. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
36. Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients.
Panasiti V; Curzio M; Roberti V; Lieto P; Devirgiliis V; Gobbi S; Naspi A; Coppola R; Lopez T; di Meo N; Gatti A; Trevisan G; Londei P; Calvieri S
Dermatology; 2013; 227(1):55-61. PubMed ID: 24008289
[TBL] [Abstract][Full Text] [Related]
37. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
[TBL] [Abstract][Full Text] [Related]
38. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
[TBL] [Abstract][Full Text] [Related]
39. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma.
Galliot-Repkat C; Cailliod R; Trost O; Danino A; Collet E; Lambert D; Vabres P; Dalac S
Eur J Surg Oncol; 2006 Sep; 32(7):790-4. PubMed ID: 16822643
[TBL] [Abstract][Full Text] [Related]
40. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]